论文部分内容阅读
目的:观察厄贝沙坦联合丹红注射液治疗糖尿病肾病(DN)的疗效。方法:将72例糖尿病肾病(DN)患者随机分为观察组34例和对照组38例,两组除给予控制血糖治疗外,观察组应用厄贝沙坦联合丹红注射液静滴,对照组单用厄贝沙坦。比较两组治疗前和治疗4周后尿白蛋白排泄率(UAER)、血肌酐(Scr)和血尿素氮(BUN)等指标的变化。结果:对照组与观察组治疗后UAER均较治疗前显著下降(P<0.05),但观察组下降更为明显(P<0.05);观察组SCR水平明显低于治疗前(P<0.05。结论:厄贝沙坦联合应用丹红注射液对DN患者有明显的降低尿蛋白,改善肾功能作用。
Objective: To observe the curative effect of irbesartan combined with Danhong injection on diabetic nephropathy (DN). Methods: Seventy-two patients with diabetic nephropathy (DN) were randomly divided into observation group (34 cases) and control group (38 cases). In addition to blood sugar control, the observation group was treated with irbesartan combined with Danhong injection and control group Irbesartan alone. Urinary albumin excretion rate (UAER), serum creatinine (Scr) and blood urea nitrogen (BUN) were measured before and 4 weeks after treatment. Results: The UAER of the control group and the observation group decreased significantly (P <0.05), but the decrease of the observation group was more obvious (P <0.05). The level of SCR in the observation group was significantly lower than that before treatment (P <0.05). : Irbesartan combined with Danhong injection in patients with DN significantly reduce urinary protein, improve renal function.